卡瑞利珠单抗联合化疗治疗老年NSCLC患者的效果分析
Effect Analysis of Carrilizumab Combined with Chemotherapy in the Treatment of Elderly Patients with NSCLC
吴星星 1刘佳 1魏洁1
作者信息
- 1. 联勤保障部队第九八九医院,河南 洛阳 471000
- 折叠
摘要
目的:探究卡瑞利珠单抗联合化疗治疗老年非小细胞肺癌(NSCLC)患者的效果.方法:将本院 96 例老年NSCLC患者按照随机数字表法分为对照组(n =48 例)和试验组(n =48 例);对照组患者接受化疗治疗,试验组患者接受化疗+卡瑞利珠单抗治疗;比较两组患者临床疗效、血清相关指标水平以及不良反应情况.结果:治疗后,试验组患者临床疗效率高于对照组(P＜0.05)、VEGF、MMP-9 以及CY211 水平低于对照组(P＜0.05),两组患者不良反应发生率差异无统计学意义(P＞0.05).结论:卡瑞利珠单抗联合化疗治疗老年NSCLC,疗效显著,药物安全较高,值得临床推广.
Abstract
Objective:To explore the efficacy of combination therapy with Carolizumab and chemotherapy in the treatment of elderly non-small cell lung cancer(NSCLC)patients.Methods:96 elderly NSCLC pa-tients in our hospital were randomly divided into a control group(n =48 cases)and an experimental group(n =48 cases)using a random number table method.The control group patients received chemotherapy treatment,while the experimental group patients received chemotherapy and treatment with Carolizumab.Compare the clin-ical efficacy,serum related indicator levels,and adverse reactions between two groups of patients.Results:Af-ter treatment,the clinical treatment efficiency of the experimental group was higher than that of the control group(P＜0.05),and the levels of VEGF,MMP-9,and CY211 were lower than those of the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion:Karelizumab combined with chemotherapy has a significant thera-peutic effect and high drug safety in the treatment of elderly NSCLC,which is worthy of clinical promotion.
关键词
卡瑞利珠单抗/非小细胞肺癌/临床疗效/不良反应Key words
Carrilizumab/Non-small cell lung cancer/Clinical efficacy/Adverse reactions引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据